Clinical Trial Update: Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of bevacizumab in patients with unresectable or metastatic kidney cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Paul Monk | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-02-18